New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
09:25 EDTLTM, NFLX, CTRP, ADNC, ELN, MAT, VVUS, TSN, DELL, ALKS, MCK, GDOT, MRKOn The Fly: Pre-market Movers
UP AFTER EARNINGS/GUIDANCE: Audience (ADNC), up 30%... Tyson Foods (TSN), up 3.3%... Ctrip.com (CTRP), up 8.5%... Green Dot (GDOT), up 6.5%... ALSO HIGHER: Dell (DELL), up 6% after Reuters says 'go private' deal may happen Monday... VIVUS (VVUS), up 5.7% after study published on weight loss drug improving cardiovascular disease risk factors... Netflix (NFLX), up 3.3% after Morgan Stanley raises price target on shares to $200... DOWN AFTER EARNINGS/GUIDANCE: Merck (MRK), down 2.9%... McKesson (MCK), down 2.1%... Mattel (MAT), down 1.7%... Life Time Fitness (LTM), down 16.4%... ALSO LOWER: Alkermes (ALKS), down 5.9% after Elan (ELN) to sell remaining stake, shares downgraded to Neutral at BofA Merrill Lynch.
News For DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 26, 2015
08:03 EDTLTMLife Time Fitness says board continues to review strategic alternatives
As previously announced, the company’s board of directors continues to review strategic alternatives, including the exploration of a conversion of real estate assets into a REIT, which the Board believes could provide substantial benefits to the company and its shareholders. The company is unable to comment further at this time but expects to provide shareholders with additional information, as appropriate.
February 25, 2015
11:47 EDTNFLXAnalysts clash on DreamWorks following Q4 miss
The shares of animated film and television show maker DreamWorks (DWA) are rising, despite the weaker than expected results reported by the company last night. Two analysts offered very different views on the company's outlook following its results. BACKGROUND: DreamWorks last night reported a fourth quarter per share loss of ($3.08), versus analysts' consensus outlook for a ($3.01) per share loss. The company's revenue also came in below expectations. Excluding $210M in pre-tax charges associated with DreamWorks' restructuring plan, its loss was (75c) per share, the company stated. BEARISH TAKE: In a note to investors today, FBR Capital analyst Barton Crockett wrote that DreamWorks' results were "ugly," as they included $155M of write-offs on films and TV shows. However, Crockett believes that the crucial factor for the company's outlook is whether it can consistently compete with the entertainment giants, including Disney (DIS), Viacom (VIA), and Time Warner (TWX). Crockett is not convinced that DreamWorks will be able to hold its own, and he believes that its 2015 results could come in below expectations. The analyst warned that the company may have difficulty meeting its 2015 consumer products revenue guidance. DreamWorks expects its consumer products revenue to double this year, but the movie-based toy space is "very competitive" in 2015, as toys based on multiple popular children's films are set to be released, Crockett stated. Moreover, after conducting checks online, Crockett reports that there does not seem to be a great deal of interest in DreamWorks' movie "Home," which is set to be released on March 27. He kept an Underperform rating on the shares and raised his price target on the stock to $14 from $12. BULLISH TAKE: DreamWorks' results were mixed, but the results are not very important, Piper Jaffray analyst James Marsh stated. The company's guidance for its TV and consumer products businesses were solid, the analyst believes. Moreover, the company "took specific and decisive action" to avert a liquidity crunch, Marsh wrote. Specifically, DreamWorks raised $185M of capital by selling its real estate in Glendale, California and then leasing it back, and increased the size of its current credit facility to $450M from $400M, Marsh reported. The moves should "largely" eliminate investors' worries about the company's liquidity position, Marsh stated. He kept a $26 price target and Overweight rating on the stock. WHAT'S NOTABLE: On DreamWorks' earnings conference call last night, the company's CEO Jeffrey Katzenberg stated that it did not obtain more than 10% of its revenue from Netflix (NFLX) last year. However, in an SEC filing earlier this morning, DreamWorks clarified that it had obtained 14.9% of its revenue from Netflix last year. PRICE ACTION: In late morning trading, DreamWorks rose 5.6% to $22.31.
11:19 EDTNFLXNetflix to premiere five new shows for kids
Netflix announced that it is adding five new animated and live-action comedy series to its selection of kids and family entertainment. These include Danger Mouse, planned for Spring 2016, Inspector Gadget in March 2015, Some Assembly Required in Summer 2015, Bottersnikes & Gumbles in Spring 2016 and SUPER 4, a new CGI animated series inspired by PLAYMOBIL, which makes its U.S. premiere in April exclusively on Netflix.
08:30 EDTALKSAlkermes price target raised to $79 from $75 at Leerink
Leerink raised its price target for Alkermes shares to $79 to reflect probability-of-success weighted ALKS 8700 in multiple sclerosis revenue. The firm views the company's Q4 results as strong, but notes its 2015 outlook missed consensus due to higher than expected operating expenses. Leerink says the 2015 guidance reflects Alkermes' maturing pipeline. It keeps an Outperform rating on the stock.
08:08 EDTMRKMerck to present new data from IMPROVE-IT, TRA 2ºP studies
Subscribe for More Information
06:19 EDTALKSAlkermes pipeline eases loss of pain program, says Citigroup
Citigroup says Alkermes' pipeline programs and the continued growth of its base business help moderate the disappointment of the discontinuation of novel pain program ALKS-7106. Citi lowered its price target for Alkermes shares to $83 from $85 and keeps a Buy rating on the stock.
05:57 EDTALKSUBS says remain on sidelines with respect to Alkermes
Subscribe for More Information
February 24, 2015
16:01 EDTVVUSVIVUS reports Q4 EPS (25c), consensus (25c)
Reports Q4 revenue $21.7M, consensus $20.01M.
10:06 EDTALKSHigh option volume stocks
High option volume stocks: CHGG LBTYK SMH RCAP NGLS OTEX TERP CNC ALKS AMT
10:01 EDTNFLXNetflix teams up with Judd Apatow for 'Pee-wee's Big Holiday'
Netflix will premiere exclusively in all of its territories the new feature film, Pee-wee's Big Holiday, starring Paul Reubens as the beloved fun-loving hero of TV, stage and film, Pee-wee Herman. Judd Apatow and Reubens, who worked together to bring the project to fruition, will produce the film. Production is slated to begin in early 2015.
08:56 EDTALKSOn The Fly: Pre-market Movers
Subscribe for More Information
08:54 EDTALKSAlkermes 7106 halt overshadows Q4 beat, says Credit Suisse
Subscribe for More Information
07:15 EDTNFLXNetflix may enter Russia within two years, Hollywood Reporter says
Netflix' head of communications in Europe, Joris Evers, says the company hopes to make its entrance in Russia within the next two years, The Hollywood Reporter says. Reference Link
07:06 EDTALKSAlkermes sees FY15 adjusted EPS 27c-40c, consensus 20c
Subscribe for More Information
07:03 EDTALKSAlkermes reports Q4 EPS 11c, consensus 4c
Subscribe for More Information
07:01 EDTALKSAlkermes announces phase 1 results for ALKS 7106, will not proceed to phase 2
Subscribe for More Information
05:17 EDTMRKMerck collaborates with Medicines Patent Pool to expand Raltegravir access
Subscribe for More Information
February 23, 2015
08:27 EDTMRKNGM Biopharmaceuticals to hold a teleconference
NGM Biopharm discusses the strategic collaboration with Merck to discover, develop and commercialize novel biologic therapeutics on a teleconference to be held on February 23 at 9:30 am. Webcast Link
07:04 EDTMRKMerck, NGM Biopharmaceuticals announce multi-year collaboration
NGM Biopharmaceuticals and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The collaboration includes multiple drug candidates currently in preclinical development at NGM, including NP201, which is being evaluated for the treatment of diabetes, obesity and nonalcoholic steatohepatitis. NGM will lead the research and development of the existing preclinical candidates and have the autonomy to identify and pursue other discovery stage programs at its discretion. Merck will have the option to license all resulting NGM programs following human proof of concept trials. If Merck exercises this option, Merck will lead global product development and commercialization for the resulting products, if approved. Under the terms of the agreement, Merck will make an upfront payment to NGM of $94M and will purchase a 15 percent equity stake in NGM for $106M at a price per share that represents a 20% premium to NGM’s most recent financing. Merck will commit up to $250M to fund all of NGM’s efforts under the initial five-year term of the collaboration, with the potential for additional funding if certain conditions are met. Prior to Merck initiating a Phase 3 study for a licensed program, NGM may elect to either receive milestone and royalty payments or, in certain cases, to co-fund development and participate in a global cost and revenue share arrangement of up to 50%. The agreement also provides NGM with the option to participate in the co-promotion of any co-funded program in the United States. Merck will have the option to extend the research agreement for two additional two-year terms.
February 20, 2015
07:08 EDTMRKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use